Home › Therapeutic areas › Oncology › Renal Cell Carcinoma
Renal Cell Carcinoma (10 companies)
Companies with an active program in Renal Cell Carcinoma.
| Ticker | Company | Therapeutic areas | Programs | Lead stage | Mkt cap | Programs |
|---|---|---|---|---|---|---|
| ALLO | Allogene Therapeutics | ImmunologyOncology Rare | 1 | Phase 2 | $360M | 10 |
| RCUS | Arcus Biosciences | DermatologyImmunology+1 | 2 | Phase 3 | $2.63B | 8 |
| CMPX | Compass Therapeutics | Oncology | 1 | Phase 2 | $137M | 15 |
| CRVS | Corvus Pharmaceuticals | DermatologyOncology+1 Rare | 1 | Phase 3 | $889M | 7 |
| EXEL | Exelixis | CardiovascularOncology | 3 | Approved | $17.0B | 23 |
| KURA | Kura Oncology | MetabolicOncology | 1 | Approved | $647M | 12 |
| NVCT | Nuvectis Pharma | HematologyOncology+1 Rare | 1 | Phase 3 | $719M | 9 |
| SMMT | Summit Therapeutics | Oncology | 1 | NDA Submitted | $13.1B | 6 |
| TLX | Telix Pharmaceuticals | Oncology | 3 | Approved | $3.27B | 25 |
| XNCR | Xencor | ImmunologyNeurology+1 Rare | 3 | Approved | $2.68B | 28 |
No companies match.